HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pozzi, O. R. Articles by Zalutsky, M. R. Search for Related Content PubMed PubMed Citation Articles by Pozzi, O. R. Articles by Zalutsky, M. R.

Radiopharmaceutical Chemistry of Targeted Radiotherapeutics, Part 1: Effects of Solvent on the Degradation of Radiohalogenation Precursors by ²¹¹At -Particles

Department of Radiology, Duke University Medical Center, Durham, North Carolina

The high energy and short range of -particles make them attractive for targeted radiotherapy. However, these properties can be problematic when the production of high activity levels of -particle–emitting radiotherapeutics is required. For example, difficulties were encountered in the production of N-succinimidyl 3-[²¹¹At]-astatobenzoate (SAB), when 370-MBq doses of ²¹¹At-labeled antibody were required. The purpose of this study was to investigate a potential cause of this behavior—radiolytic degradation of the radiohalogenation precursor. Methods: Both N-succinimidyl 3-(tri-n-butylstannyl)benzoate (BuSTB) and N-succinimidyl 3-trimethylstannylbenzoate (MeSTB) were incubated with various ²¹¹At time–activity combinations such that the radiation dose received by the reaction medium ranged from about 0 to 20,000 Gy. Studies were performed using chloroform, methanol, and benzene as the solvent, and both at neutral pH and at a pH of 5.5, as used in SAB synthesis. The fraction of tin precursor remaining and the generation of unlabeled byproducts were determined from high-performance liquid chromatograms and then plotted against radiation dose. Results: Extensive radiolytic decomposition of BuSTB and MeSTB was observed in chloroform, with 50% degradation taking place even at doses below 500 Gy. Formation of a byproduct, most likely N-succinimidyl 3-chlorobenzoate, increased with radiation dose. A greater degree of stability was seen in both methanol and benzene, with more than 85% of the precursor remaining at 3,500 Gy. No cold byproducts were observed with either solvent. Conclusion: The nature of the solvent profoundly influences the ability to synthesize high activity levels of SAB and possibly other ²¹¹At-labeled radiopharmaceuticals.

Key Words: -particles • ²¹¹At • radioloysis • radionuclide therapy

Related articles in JNM:

THIS MONTH IN JNM

JNM 2005 46: 8a-9a. [Full Text]  

This article has been cited by other articles:

				S. Lindegren, S. Frost, T. Back, E. Haglund, J. Elgqvist, and H. Jensen Direct Procedure for the Production of 211At-Labeled Antibodies with an {varepsilon}-Lysyl-3-(Trimethylstannyl)Benzamide Immunoconjugate J. Nucl. Med., September 1, 2008; 49(9): 1537 - 1545. [Abstract] [Full Text] [PDF]

				O. R. Pozzi and M. R. Zalutsky Radiopharmaceutical Chemistry of Targeted Radiotherapeutics, Part 3: {alpha}-Particle-Induced Radiolytic Effects on the Chemical Behavior of 211At J. Nucl. Med., July 1, 2007; 48(7): 1190 - 1196. [Abstract] [Full Text] [PDF]

				M. J. Welch Potential and Pitfalls of Therapy with {alpha}-Particles J. Nucl. Med., August 1, 2005; 46(8): 1254 - 1255. [Full Text] [PDF]